(Reuters) – Denmark-based Ascendis Pharma A/S said on Monday the U.S. Food & Drug Administration (FDA) had declined to approve its experimental therapy to treat adult patients with a hormone disorder called hypoparathyroidism.
(Reporting by Mariam Sunny in Bengaluru; Editing by Anil D’Silva)
